Soligenix, Inc. (NASDAQ:SNGX) Short Interest Up 280.9% in April

Soligenix, Inc. (NASDAQ:SNGX) saw a significant growth in short interest in April. As of April 15th, there was short interest totalling 177,500 shares, a growth of 280.9% from the March 31st total of 46,600 shares. Based on an average trading volume of 84,300 shares, the short-interest ratio is currently 2.1 days. Approximately 5.6% of the company’s stock are short sold.

Institutional Trading of Soligenix

A hedge fund recently raised its stake in Soligenix stock. Geode Capital Management LLC grew its position in Soligenix, Inc. (NASDAQ:SNGX) by 42.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 26,094 shares of the biopharmaceutical company’s stock after acquiring an additional 7,729 shares during the period. Geode Capital Management LLC owned 1.04% of Soligenix worth $71,000 at the end of the most recent reporting period. Institutional investors own 3.60% of the company’s stock.

Soligenix Stock Performance

Shares of SNGX stock traded up $0.04 during trading hours on Tuesday, hitting $2.11. 2,840 shares of the company were exchanged, compared to its average volume of 760,256. The stock has a market capitalization of $5.28 million, a price-to-earnings ratio of -0.28 and a beta of 1.85. Soligenix has a one year low of $1.68 and a one year high of $14.83. The business’s 50-day simple moving average is $2.18 and its two-hundred day simple moving average is $2.77.

Soligenix (NASDAQ:SNGX) last posted its quarterly earnings data on Friday, March 21st. The biopharmaceutical company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.19). Soligenix had a negative return on equity of 223.29% and a negative net margin of 1,473.38%. The firm had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.20 million. During the same period in the prior year, the firm posted ($12.66) EPS. As a group, analysts anticipate that Soligenix will post -4.65 EPS for the current fiscal year.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.